Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Insider Selling Spree Rattles MACOM Investors Ahead of Earnings

Dieter Jaworski by Dieter Jaworski
November 1, 2025
in Earnings, Insider Trading, Semiconductors
0
Macom Stock
0
SHARES
20
VIEWS
Share on FacebookShare on Twitter

MACOM Technology Solutions shares are facing significant pressure following substantial stock sales by a major shareholder just days before the company’s quarterly results announcement. The timing of these transactions has sparked concern among market participants.

Leadership Transition and Massive Stock Disposal

Former director Susan Ocampo executed sales totaling over $18 million during two consecutive trading days last week. She divested 132,873 shares at prices ranging from $148.02 to $150.01 per share. Market reaction was immediate, with the stock declining to $150.61, retreating from its recent all-time peak of $152.66.

This development follows Ocampo’s recent departure from the board of directors in late August after fifteen years of service. The convergence of leadership changes and substantial insider selling has created uncertainty throughout the investment community.

Financial Performance and Forward Guidance

Concurrent with these transactions, MACOM released earnings guidance for the fourth quarter. The company projects earnings per share between $0.910 and $0.950. This forecast builds upon a robust third-quarter performance where MACOM exceeded expectations with EPS of $0.90 against projections of $0.89.

Should investors sell immediately? Or is it worth buying Macom?

Revenue showed impressive momentum, climbing 32.3% year-over-year to reach $252.08 million. However, questions remain about whether this growth trajectory sufficiently supports current valuation levels.

Market Analysts Express Divergent Views

Research analysts maintain mixed perspectives on MACOM’s outlook. While the consensus rating stands at “Moderate Buy,” price targets display considerable variation from $136 to $155 per share. TD Cowen recently highlighted growth opportunities in key sectors including electronic warfare systems, radar technology, and data center infrastructure.

Technical indicators now suggest potential headwinds. After reaching record highs, the stock is showing early signs of exhaustion. All eyes turn to Thursday’s quarterly earnings release, which will prove crucial in determining whether the company can restore confidence following the unsettling insider sales activity.

Ad

Macom Stock: Buy or Sell?! New Macom Analysis from February 7 delivers the answer:

The latest Macom figures speak for themselves: Urgent action needed for Macom investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Macom: Buy or sell? Read more here...

Tags: Macom
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

ServiceNow Stock
AI & Quantum Computing

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026
Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
Myers Industries Stock
Analysis

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
Next Post
Outfront Media Stock

High-Yield Opportunity: Outfront Media Shares Offer 7% Dividend

C3.ai Stock

C3.ai Shares Plunge Amidst Financial Turmoil and Leadership Shakeup

Redcare Pharmacy Stock

Redcare Pharmacy Shares Tumble Despite Record Performance

Recommended

C3.ai Stock

Is C3.ai Stock Poised for a Rebound?

2 months ago
MMM stock news

Clarification on Hyperlink and Promotional Fees

2 years ago

XOMA Corporation Expands Portfolio with Acquisition of DSUVIA

2 years ago
Microsoft Stock

A Bold Bet: Peter Thiel’s Hedge Fund Doubles Down on Microsoft

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

ServiceNow Shares Face Market Skepticism Despite Record Performance

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

A New Chapter for First Busey as CrossFirst Merger Finalizes

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Trending

Avanos Medical Stock
Analysis

Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

by SiterGedge
February 7, 2026
0

Avanos Medical is navigating a critical strategic transformation. The medical device firm is streamlining its operations to...

Guaranty Bancshares Stock

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

February 7, 2026
Yirendai Stock

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
ServiceNow Stock

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026
Orthofix Medical Stock

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth
  • Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion
  • Yirendai Charts a New Course with Tech-Driven Strategy

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com